This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Citigroup analyst Patrick Donnelly downgraded Quest Diagnostics Incorporated DGX from Buy to Neutral and maintained the price target of $185. Quest Diagnostics shares closed at $176.95 on Monday. See how other analysts view this stock.
  • UBS analyst Manav Gupta downgraded the rating for Green Plains Inc. GPRE from Buy to Neutral and announced a $7 price target. Green Plains shares closed at $5.41 on Monday. See how other analysts view this stock.
  • Needham analyst Joseph Stringer downgraded Pliant Therapeutics, Inc. PLRX from Buy to Hold and maintained the price target of $10. Pliant Therapeutics shares closed at $1.38 on Monday. See how other analysts view this stock.
  • B of A Securities analyst Craig Bijou downgraded the rating for Teleflex Incorporated TFX from Neutral to Underperform and lowered the price target from $235 to $140. Teleflex shares closed at $135.13 on Monday. See how other analysts view this stock.
  • Barclays analyst Ramsey El-Assal downgraded AvidXchange Holdings, Inc AVDX from Overweight to Equal-Weight and lowered the price target from $13 to $8. AvidXchange shares closed at $7.42 on Monday. See how other analysts view this stock.

Read This Next:

Loading...
Loading...
AVDX Logo
AVDXAvidXchange Holdings Inc
$9.74-%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
27.60
Growth
81.27
Quality
-
Value
14.63
Price Trend
Short
Medium
Long
Got Questions? Ask
Which healthcare stocks might benefit from downgrades?
How will Quest Diagnostics impact diagnostics sector?
Is there potential in Green Plains after downgrade?
Could Pliant Therapeutics rebound after analyst's view?
What are the risks for Teleflex now?
Will AvidXchange recover after its rating change?
Which investment strategies work best with downgrades?
How might biotech stocks be affected by downgrades?
Which analysts' ratings should investors track for insights?
Are there opportunities in defensive stocks now?
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Comments
Loading...